US 11,884,626 B2
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
Anthony C. Blackburn, San Diego, CA (US); Ryan O. Castro, San Diego, CA (US); Mark Allen Hadd, San Diego, CA (US); You-An Ma, Poway, CA (US); Antonio Garrido Montalban, San Diego, CA (US); Jaimie Karyn Rueter, San Diego, CA (US); Lee Alani Selvey, Longview, WA (US); Sagar Raj Shakya, San Diego, CA (US); and Marlon Carlos, Chula Vista, CA (US)
Assigned to Arena Pharmaceuticals, Inc., New York, NY (US)
Filed by Arena Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,063.
Application 17/375,063 is a continuation of application No. 16/862,681, filed on Apr. 30, 2020, granted, now 11,091,435.
Application 16/862,681 is a continuation of application No. 16/379,265, filed on Apr. 9, 2019, granted, now 10,676,435, issued on Jun. 9, 2020.
Application 16/379,265 is a continuation of application No. 15/738,175, granted, now 10,301,262, issued on May 28, 2019, previously published as PCT/US2016/038506, filed on Jun. 21, 2016.
Claims priority of provisional application 62/207,531, filed on Aug. 20, 2015.
Claims priority of provisional application 62/182,841, filed on Jun. 22, 2015.
Prior Publication US 2022/0002244 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/94 (2006.01); C07C 279/12 (2006.01)
CPC C07D 209/94 (2013.01) [C07C 279/12 (2013.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A method for treating an S1P1 receptor-associated disorder in an individual comprising administering to the individual in need thereof a therapeutically effective amount of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit substantially free of radial clusters or spherulites, wherein the S1P1 receptor-associated disorder is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.